Sucralose Affects Glycemic and Hormonal Responses to an Oral Glucose Load

Very Low–Calorie Diet Mimics the Early Beneficial Effect of Roux-en-Y Gastric Bypass on Insulin Sensitivity and β-Cell Function in Type 2 Diabetic Patients

ADA: 4/22/13

Marked improvement in glycemic control occurs in patients with type 2 diabetes mellitus shortly after Roux-en-Y gastric bypass surgery (RYGB) and before there is major weight loss. The objective of this study was to determine whether the magnitude of this change is primarily due to caloric restriction or is unique to the surgical procedure. We studied eleven subjects who underwent RYGB and fourteen subjects mean-matched for BMI, HbA_1c, and diabetes duration who were admitted to our inpatient research unit and given a very low–calorie diet (VLCD) of 500 kcal/day with a macronutrient content similar to that consumed by patients after RYGB. Frequently sampled intravenous glucose tolerance tests were performed before and after interventions. Both groups lost an equivalent amount of weight over a mean study period of 21 days. Insulin sensitivity, acute insulin secretion after intravenous glucose administration, and β-cell function as determined by disposition index improved to a similar extent in both groups. Likewise, changes in fasting glucose and fructosamine levels were similar.Read more

Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications

Ajpmonline: AUGUST 6, 2013

Background: Lifetime direct medical cost of treating type 2 diabetes and diabetic complications in the U.S. is unknown.

Purpose: This study provides nationally representative estimates of lifetime direct medical costs of treating type 2 diabetes and diabetic complications in people newly diagnosed with type 2 diabetes, by gender and by age at diagnosis.

Methods: A type 2 diabetes simulation model was used to simulate the disease progression and direct medical costs among a cohort of newly diagnosed type 2 diabetes patients. The study sample used for the simulation was based on data from the 2009–2010 National Health and Nutritional Examination Survey. The costs of treating type 2 diabetes and diabetic complications were derived from published literature. Annual medical costs were accumulated over the life span of type 2 diabetes to determine the lifetime medical costs. All costs were calculated from a healthcare system perspective, and expressed in 2012 dollars. Read more

Nova Max Glucose Test Strips: Recall – May Report False, Abnormally High Blood Glucose Result

FDA: [Posted 07/29/2013]

AUDIENCE: Consumer, Family Physician, Pharmacy

ISSUE: Nova Diabetes Care initiated a voluntary recall of 21 lots of the Nova Max Glucose Test Strips distributed both in the USA and outside the continental USA. Nova Max Plus glucose meter kits that include test strips from the recalled lots are also included in this voluntary recall.

The company has recently determined that some of the blood glucose test strips contained within the indicated Nova Max Glucose Test Strip lots and Nova Max Plus glucose meter kits may report a false, abnormally high blood glucose result. A false abnormally high blood glucose result could, under certain conditions, result in an insulin dosing error that could lead to a serious health risk requiring immediate medical attention.

BACKGROUND: Upon identifying the issue, Nova Diabetes Care promptly notified all registered users, health care professionals, pharmacies, and distributors where the Nova Max Glucose Test Strip and Nova Max Plus glucose meter kit are recommended or sold. Read more

Prevalence of Diagnosed and Undiagnosed Type 2 Diabetes Mellitus Among US Adolescents: Results from the Continuous NHANES, 1999–2010

Oxford Journals: July 25, 2013

Although prevalence and incidence of type 2 diabetes mellitus (T2DM) are reportedly increasing among adolescents, national data are lacking, particularly in regard to undiagnosed T2DM. To estimate the prevalence of diagnosed and undiagnosed T2DM among US adolescents, we analyzed a nationally representative cross-section of 11,888 adolescents aged 12–19 years who received a diabetes interview in the Continuous National Health and Nutrition Examination Survey during 1999–2010. Among them, a random subsample of 4,661 adolescents also had fasting blood samples collected. Persons who reported a previous diabetes diagnosis and were either taking no medication or taking an oral hypoglycemic agent (with or without insulin) were classified as having T2DM; persons who reported using insulin alone were classified as having type 1 diabetes. read more

The hidden cost of moving up: Type 2 diabetes and the escape from persistent poverty in the American South

Diabetes in America: An Analysis of an Epidemic

Grey House: 4/1/13

The First in Grey House’s new Health in America series, Diabetes in America: Analysis of an Epidemic charts the geographic and demographic prevalence of people with Diabetes nationwide, by state and by district. This important title provides the reader with statistical comparisons of incidence, prevalence, costs and other relevant analysis of Diabetes across the US – at the nation, state and district level.

Diabetes in America: Analysis of an Epidemic:

• Provides National, State and Congressional District Profiles of the Prevalence of Diabetes across the country
• Each profile begins with a Four-Color Map charting the prevalence of Diabetes, along with the contact information and photo of the leading government official for that area
• Profiles also provide detailed statistics, all arranged by age, gender and race/ethnicity on the Number of Diabetics, Overall Prevalence, Percent Uninsured, Number of Hospital Encounters, Hospitalization Costs, Total Annual Meidcal Costs, along with the percentage who have their Diabetes under control
• Comparative Ranking Charts compare all of these statistics at the national, state and congressional district levelNEW! Buyers of the Print Edition get FREE ONLINE ACCESS at http://gold.greyhouse.com